Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

CHEIRON study: Docetaxel plus enzalutamide versus docetaxel as first-line chemotherapy for patients with mCRPC

TRITON2: Evaluation of rucaparib in patients with metastatic castration-resistant prostate cancer

IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA

Assessing radiotherapy for men with newly diagnosed metastatic prostate cancer

ESMO 2018: Highlights

Comment on the JAVELIN study: RCC immunotherapy

Comment: Radiotherapy as a treatment option for metastatic prostate cancer

JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma